Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP (PARTNERUP)
Opioid Use, Opioid Use Disorder, Risk Reduction
About this trial
This is an interventional health services research trial for Opioid Use focused on measuring opioid, medication for opioid use disorder, Drug user health hub, syringe services program, syringe exchange, PrEP, HIV prevention, retention in care, Suboxone, Hepatitis C treatment, hepatitis C, Opioid use disorder, feasibility, acceptability
Eligibility Criteria
Inclusion Criteria:
- 18 years or older
- Participant in SSP
- History of self-report injection opioid use in the past 6 months
- Willing to take bup/nx, PrEP, and/or hepatitis C treatment for 6 months
- Not currently taking PrEP
- HIV negative
- Not pregnant
Either a history of sharing injection or drug preparation equipment or risk of sexual acquisition of HIV* in the past 6 months
*Individuals are considered at risk of sexual acquisition of HIV if they answer yes to any of the items in the below question: In the last 6 months, have any of the following applied to you?
- Traded sex for money or drugs
- Had a sexual partner who is HIV positive
- Did not consistently use condoms when having sex
- Had a bacterial sexually transmitted infections (like gonorrhea, chlamydia, or syphilis)
- No medical contraindications for these medications such as history of renal failure or bone diseases
Exclusion Criteria:
- Have altered mental status in which participant cannot sign a consent form
- Receive a positive pregnancy test (will be checked at screening visit)
- Receive a positive HIV test at enrollment (will be checked at screening visit)
- Have evidence of renal failure (will be checked at screening visit)
- Have a history of hepatitis B (will be checked at screening visit)
- Becoming incarcerated during the study
Additional considerations:
The following are not exclusion criteria for the study overall, but will affect which treatment(s) they can receive:
- Are currently receiving some form of MOUD (buprenorphine, naltrexone, methadone) - this makes them ineligible for MOUD treatment through the study, but they can still receive PrEP and/or hepatitis C treatment
- Have received treatment for hepatitis C prior to enrollment - this makes them ineligible for hepatitis C treatment through study, but they can still receive PrEP and/or MOUD
Sites / Locations
- Duke Department of Population Health Sciences
- NC Survivors Union
Arms of the Study
Arm 1
Experimental
Medication and telemedicine follow up
Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.